Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.89
NYSE:PFE's Cash to Debt is ranked higher than
59% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. NYSE:PFE: 0.89 )
NYSE:PFE' s 10-Year Cash to Debt Range
Min: 0.14   Max: 3.47
Current: 0.89

0.14
3.47
Equity to Asset 0.44
NYSE:PFE's Equity to Asset is ranked higher than
51% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. NYSE:PFE: 0.44 )
NYSE:PFE' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.62
Current: 0.44

0.39
0.62
Interest Coverage 11.11
NYSE:PFE's Interest Coverage is ranked higher than
54% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 90.51 vs. NYSE:PFE: 11.11 )
NYSE:PFE' s 10-Year Interest Coverage Range
Min: 5.27   Max: 46.18
Current: 11.11

5.27
46.18
F-Score: 5
Z-Score: 2.57
M-Score: -2.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 30.47
NYSE:PFE's Operating margin (%) is ranked higher than
96% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. NYSE:PFE: 30.47 )
NYSE:PFE' s 10-Year Operating margin (%) Range
Min: 9.51   Max: 35.89
Current: 30.47

9.51
35.89
Net-margin (%) 42.65
NYSE:PFE's Net-margin (%) is ranked higher than
97% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. NYSE:PFE: 42.65 )
NYSE:PFE' s 10-Year Net-margin (%) Range
Min: 8.74   Max: 42.65
Current: 42.65

8.74
42.65
ROE (%) 28.83
NYSE:PFE's ROE (%) is ranked higher than
98% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. NYSE:PFE: 28.83 )
NYSE:PFE' s 10-Year ROE (%) Range
Min: 5.98   Max: 52.59
Current: 28.83

5.98
52.59
ROA (%) 12.78
NYSE:PFE's ROA (%) is ranked higher than
96% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.95 vs. NYSE:PFE: 12.78 )
NYSE:PFE' s 10-Year ROA (%) Range
Min: 3.35   Max: 25.31
Current: 12.78

3.35
25.31
ROC (Joel Greenblatt) (%) 83.18
NYSE:PFE's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.63 vs. NYSE:PFE: 83.18 )
NYSE:PFE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 19.53   Max: 88.78
Current: 83.18

19.53
88.78
Revenue Growth (%) -2.50
NYSE:PFE's Revenue Growth (%) is ranked higher than
56% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. NYSE:PFE: -2.50 )
NYSE:PFE' s 10-Year Revenue Growth (%) Range
Min: -2.5   Max: 19.1
Current: -2.5

-2.5
19.1
EBITDA Growth (%) 11.80
NYSE:PFE's EBITDA Growth (%) is ranked higher than
78% of the 504 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. NYSE:PFE: 11.80 )
NYSE:PFE' s 10-Year EBITDA Growth (%) Range
Min: -4.7   Max: 35.5
Current: 11.8

-4.7
35.5
EPS Growth (%) 17.00
NYSE:PFE's EPS Growth (%) is ranked higher than
80% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. NYSE:PFE: 17.00 )
NYSE:PFE' s 10-Year EPS Growth (%) Range
Min: -26.8   Max: 90.5
Current: 17

-26.8
90.5
» NYSE:PFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

PFE Guru Trades in Q2 2013

Mark Hillman 23,982 sh (New)
John Buckingham 34,603 sh (New)
Steven Cohen 1,686,335 sh (+236.67%)
Ruane Cunniff 10,422 sh (+13.94%)
James Barrow 60,830,964 sh (+4.37%)
Jeremy Grantham 58,022,697 sh (+4.12%)
John Keeley 107,170 sh (+2.63%)
Manning & Napier Advisors, Inc 1,117,337 sh (+1.67%)
Ken Fisher 30,739,957 sh (+0.09%)
Ronald Muhlenkamp 36,364 sh (unchged)
Steven Cohen 800,000 sh (unchged)
Steven Cohen 725,000 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Paul Tudor Jones 650,000 sh (unchged)
Robert Bruce 432,000 sh (unchged)
Tom Russo Sold Out
Ray Dalio Sold Out
George Soros Sold Out
Yacktman Fund Sold Out
Richard Snow Sold Out
Alan Fournier Sold Out
Yacktman Focused Fund Sold Out
Caxton Associates Sold Out
Murray Stahl 58,880 sh (-0.08%)
Bill Frels 2,619,973 sh (-0.12%)
HOTCHKIS & WILEY 205,000 sh (-0.29%)
Irving Kahn 2,541,622 sh (-1.2%)
Jeff Auxier 166,874 sh (-1.76%)
Dodge & Cox 68,191,798 sh (-2.25%)
Charles Brandes 6,471,866 sh (-3.01%)
NWQ Managers 12,732,778 sh (-7.84%)
Mario Gabelli 1,052,288 sh (-8.8%)
RS Investment Management 2,126,155 sh (-9.06%)
Diamond Hill Capital 7,951,442 sh (-9.85%)
David Dreman 71,097 sh (-21.76%)
Vanguard Health Care Fund 23,968,323 sh (-24.15%)
Pioneer Investments 9,977,357 sh (-30.76%)
Michael Price 347,100 sh (-41.38%)
Jean-Marie Eveillard 3,017,033 sh (-54.03%)
Joel Greenblatt 18,092 sh (-66.69%)
Paul Tudor Jones 197,700 sh (-89.18%)
Donald Yacktman 41,700 sh (-99.74%)
» More
Q3 2013

PFE Guru Trades in Q3 2013

Louis Moore Bacon 17,687 sh (New)
Ray Dalio 54,608 sh (New)
Paul Tudor Jones 950,000 sh (+380.53%)
Joel Greenblatt 65,050 sh (+259.55%)
Jean-Marie Eveillard 8,276,410 sh (+174.32%)
John Buckingham 60,187 sh (+73.94%)
Mario Gabelli 1,202,843 sh (+14.31%)
Diamond Hill Capital 7,992,003 sh (+0.51%)
Manning & Napier Advisors, Inc 1,119,010 sh (+0.15%)
David Dreman 71,195 sh (+0.14%)
James Barrow 60,897,666 sh (+0.11%)
Prem Watsa 235,000 sh (unchged)
Jeff Auxier 166,874 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
Ruane Cunniff 10,422 sh (unchged)
Mark Hillman 23,982 sh (unchged)
Robert Bruce 432,000 sh (unchged)
Michael Price 347,100 sh (unchged)
Donald Yacktman 41,700 sh (unchged)
Ken Fisher 30,714,170 sh (-0.08%)
Murray Stahl 58,665 sh (-0.37%)
John Keeley 106,620 sh (-0.51%)
RS Investment Management 2,105,755 sh (-0.96%)
Dodge & Cox 67,406,435 sh (-1.15%)
Irving Kahn 2,508,002 sh (-1.32%)
Bill Frels 2,584,820 sh (-1.34%)
HOTCHKIS & WILEY 202,100 sh (-1.41%)
Charles Brandes 6,360,407 sh (-1.72%)
Ronald Muhlenkamp 34,944 sh (-3.9%)
Pioneer Investments 9,473,843 sh (-5.05%)
Vanguard Health Care Fund 21,393,422 sh (-10.74%)
NWQ Managers 11,116,160 sh (-12.7%)
Jeremy Grantham 47,726,111 sh (-17.75%)
Steven Cohen 113,826 sh (-93.25%)
» More
Q4 2013

PFE Guru Trades in Q4 2013

Jim Simons 7,499,841 sh (New)
Joel Greenblatt 222,280 sh (+241.71%)
Ray Dalio 110,408 sh (+102.18%)
Ronald Muhlenkamp 45,129 sh (+29.15%)
Jean-Marie Eveillard 10,186,005 sh (+23.07%)
Ruane Cunniff 11,022 sh (+5.76%)
Murray Stahl 61,605 sh (+5.01%)
John Buckingham 63,034 sh (+4.73%)
Robert Bruce 452,000 sh (+4.63%)
Diamond Hill Capital 8,339,063 sh (+4.34%)
James Barrow 61,461,287 sh (+0.93%)
Prem Watsa 235,000 sh (unchged)
Mark Hillman 23,982 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
Michael Price 347,100 sh (unchged)
Louis Moore Bacon Sold Out
Donald Yacktman Sold Out
Ken Fisher 30,626,382 sh (-0.29%)
Bill Frels 2,570,105 sh (-0.57%)
Mario Gabelli 1,183,743 sh (-1.59%)
RS Investment Management 2,072,255 sh (-1.59%)
John Keeley 104,466 sh (-2.02%)
Dodge & Cox 65,289,814 sh (-3.14%)
HOTCHKIS & WILEY 194,900 sh (-3.56%)
NWQ Managers 10,684,522 sh (-3.88%)
Jeff Auxier 159,324 sh (-4.52%)
Pioneer Investments 9,027,655 sh (-4.71%)
Manning & Napier Advisors, Inc 1,027,334 sh (-8.19%)
Steven Cohen 103,596 sh (-8.99%)
Charles Brandes 5,767,402 sh (-9.32%)
Irving Kahn 1,899,759 sh (-24.25%)
Vanguard Health Care Fund 12,153,122 sh (-43.19%)
Jeremy Grantham 26,803,828 sh (-43.84%)
David Dreman 10,163 sh (-85.73%)
Paul Tudor Jones 46,247 sh (-95.13%)
» More
Q1 2014

PFE Guru Trades in Q1 2014

Brian Rogers 12,287,115 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:PFE

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-12-31 Reduce -43.19%0.91%$28.24 - $32.2 $ 30.25-2%12153122
Charles Brandes 2013-12-31 Reduce -9.32%0.22%$28.24 - $32.2 $ 30.25-2%5767402
Jean-Marie Eveillard 2013-12-31 Add 23.07%0.16%$28.24 - $32.2 $ 30.25-2%10186005
David Dreman 2013-12-31 Reduce -85.73%0.15%$28.24 - $32.2 $ 30.25-2%10163
Joel Greenblatt 2013-12-31 Add 241.71%0.11%$28.24 - $32.2 $ 30.25-2%222280
Ronald Muhlenkamp 2013-12-31 Add 29.15%0.05%$28.24 - $32.2 $ 30.25-2%45129
Donald Yacktman 2013-12-31 Sold Out 0.01%$28.24 - $32.2 $ 30.25-2%0
Ray Dalio 2013-12-31 Add 102.18%0.01%$28.24 - $32.2 $ 30.25-2%110408
Jean-Marie Eveillard 2013-09-30 Add 174.32%0.44%$27.65 - $29.67 $ 30.255%8276410
Vanguard Health Care Fund 2013-09-30 Reduce -10.74%0.27%$27.65 - $29.67 $ 30.255%21393422
Joel Greenblatt 2013-09-30 Add 259.55%0.04%$27.65 - $29.67 $ 30.255%65050
Ray Dalio 2013-09-30 New Buy0.01%$27.65 - $29.67 $ 30.255%54608
Yacktman Fund 2013-06-30 Sold Out 2.65%$27.23 - $31.08 $ 30.254%0
Donald Yacktman 2013-06-30 Reduce -99.74%2.39%$27.23 - $31.08 $ 30.254%41700
Yacktman Focused Fund 2013-06-30 Sold Out 2.21%$27.23 - $31.08 $ 30.254%0
Michael Price 2013-06-30 Reduce -41.38%0.91%$27.23 - $31.08 $ 30.254%347100
Vanguard Health Care Fund 2013-06-30 Reduce -24.15%0.87%$27.23 - $31.08 $ 30.254%23968323
Jean-Marie Eveillard 2013-06-30 Reduce -54.03%0.34%$27.23 - $31.08 $ 30.254%3017033
James Barrow 2013-06-30 Add 4.37%0.12%$27.23 - $31.08 $ 30.254%60830964
George Soros 2013-06-30 Sold Out 0.06%$27.23 - $31.08 $ 30.254%0
Joel Greenblatt 2013-06-30 Reduce -66.69%0.05%$27.23 - $31.08 $ 30.254%18092
David Dreman 2013-06-30 Reduce -21.76%0.02%$27.23 - $31.08 $ 30.254%71097
Ray Dalio 2013-06-30 Sold Out 0.02%$27.23 - $31.08 $ 30.254%0
Jean-Marie Eveillard 2013-03-31 Add 57.8%0.23%$25.079 - $28.86 $ 30.2511%6562712
Ray Dalio 2013-03-31 Reduce -26.27%0.01%$25.079 - $28.86 $ 30.2511%57808
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Pfizer Inc

Donald Yacktman Comments on Pfizer - Sep 09, 2013

Pfizer (PFE) was removed from the funds due to price appreciation. The company has struggled to grow over time as it has not has not been able to produce enough new drug revenues to offset major patent expirations like Lipitor. Despite the lack of growth, the stock has appreciated significantly, and we do not think it represents a good value at current prices.

From Yacktman Funds' second quarter 2013 commentary.
Check out Donald Yacktman latest stock trades

Top Ranked Articles about Pfizer Inc

AT&T and Pfizer Top GuruFocus Dividend Growers of the Week
During the past week, GuruFocus recognized five companies as dividend growers. In order to be qualified for this list, the company had to:
Read more...
Top Five Guru-Held Health Care Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which health care companies are held by the most gurus. As of the third quarter, the following five health care companies are held by the largest number of gurus. Read more...
Vanguard Health Care Fund Selling Update
The updated portfolio of the Vanguard Health Care Fund lists 92 stocks, four of them new, a total value at $29.45 billion, and a quarter-over-quarter turnover of 4%. The portfolio is weighted with two sectors: health care at 91.5% and consumer defensive at 2.9%. Vanguard Health Care Fund has averaged a return of 24.96% over 12 months and 9.5% over 10 years, according to the GuruFocus Score Board of Gurus. Read more...
GuruFocus' Weekly Dividend Growers Pt. 2
During the past week, GuruFocus recognized 10 companies as dividend growers. In order to be qualified for this list, the company had to: Read more...
Passion and Compassion - Paul Tudor Jones, Sells in Review
Passion and compassion are the two engines that drive "venture philanthropist" Paul Tudor Jones II, founder, chairman and CEO of The Tudor Group. Passion fuels his vocation as a hedge fund trader extraordinaire. As of this month, Jones has amassed a personal fortune of around $3.7 billion, according to Forbes. Compassion clearly energizes his avocation, helping homeless children and the poor. Paul Tudor Jones is the founder of Robin Hood, a charitable organization formed in 1988 to target poverty in New York City. Its board of directors is peopled with a number of Guru billionaire investors. In his 2011 speech at the Robin Hood Heroes Breakfast, Jones outlined the various kinds of poverty, the worst being a poverty of opportunity Americans are facing. Last year, Robin Hood invested $132 million in 210 poverty-fighting programs. Read more...
Pennant Capital Sells in Review
The updated portfolio of value investor Alan Fournier, fund manager of Pennant Capital Management, lists 46 stocks, eight of them new. His portfolio has a total value of $5.57 billion, with a quarter-over-quarter turnover of 15%. Pennant Capital currently invests in technology with a sector weighting of 26.3%, consumer cyclical at 25.3%, healthcare at 8.9% and financial services at 6.8%. Read more...
The Stocks the Most Gurus Sold While the Fewest Bought
A new feature introduced yesterday filters for the net buys of investment gurus – those with the most buys minus sells. The Net Buys S&P 500 screener also tracks the most net sold stocks. According to the screener, the stocks the most gurus discarded while the fewest bought during the second quarter were: Disney (DIS), Pfizer (PFE), AIG (AIG), News Corp. (NWSA) and Goldman Sachs (GS). Read more...
Donald Yacktman Comments on Pfizer
Pfizer (PFE) was removed from the funds due to price appreciation. The company has struggled to grow over time as it has not has not been able to produce enough new drug revenues to offset major patent expirations like Lipitor. Despite the lack of growth, the stock has appreciated significantly, and we do not think it represents a good value at current prices. Read more...
The Most-Sold Guru Stocks of the Second Quarter
Now that the portfolios of all investing gurus that GuruFocus covers are in, the major trends of their buying and selling in the second quarter begin to surface. Having published the most-bought stocks of the second quarter earlier in the week, the following will list the most-sold stocks. Read more...
AMG Buys Majority Stake in Yacktman Company – Seamless Transition
A Texan, a Guru and a billionaire, Donald Yacktman is the president and co-chief investment officer of Yacktman Asset Management Co, based in Austin, Texas. He is also a co-manager for The Yacktman Funds, including the Yacktman Fund and the Yacktman Focused Fund, both of which have joined the Managers Investment Group. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 9.40
PFE's P/E(ttm) is ranked higher than
95% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.60 vs. PFE: 9.40 )
PFE' s 10-Year P/E(ttm) Range
Min: 7.67   Max: 200.11
Current: 9.4

7.67
200.11
P/B 2.50
PFE's P/B is ranked higher than
66% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. PFE: 2.50 )
PFE' s 10-Year P/B Range
Min: 1.32   Max: 4.55
Current: 2.5

1.32
4.55
P/S 4.04
PFE's P/S is ranked lower than
58% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. PFE: 4.04 )
PFE' s 10-Year P/S Range
Min: 1.72   Max: 6.47
Current: 4.04

1.72
6.47
PFCF 12.30
PFE's PFCF is ranked higher than
90% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.79 vs. PFE: 12.30 )
PFE' s 10-Year PFCF Range
Min: 5.02   Max: 35.16
Current: 12.3

5.02
35.16
EV-to-EBIT 13.50
PFE's EV-to-EBIT is ranked higher than
78% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. PFE: 13.50 )
PFE' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 69.7
Current: 13.5

7.9
69.7
PEG 2.10
PFE's PEG is ranked higher than
71% of the 309 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. PFE: 2.10 )
PFE' s 10-Year PEG Range
Min: 1.14   Max: 584
Current: 2.1

1.14
584
Shiller P/E 17.70
PFE's Shiller P/E is ranked higher than
80% of the 363 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.59 vs. PFE: 17.70 )
PFE' s 10-Year Shiller P/E Range
Min: 8.49   Max: 36.65
Current: 17.7

8.49
36.65

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.24
PFE's Dividend Yield is ranked higher than
91% of the 418 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.38 vs. PFE: 3.24 )
PFE' s 10-Year Dividend Yield Range
Min: 1.54   Max: 10.4
Current: 3.24

1.54
10.4
Dividend Payout 0.58
PFE's Dividend Payout is ranked lower than
57% of the 376 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. PFE: 0.58 )
PFE' s 10-Year Dividend Payout Range
Min: 0.3   Max: 1.11
Current: 0.58

0.3
1.11
Dividend growth (3y) 10.10
PFE's Dividend growth (3y) is ranked higher than
83% of the 235 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. PFE: 10.10 )
PFE' s 10-Year Dividend growth (3y) Range
Min: -14.7   Max: 22.6
Current: 10.1

-14.7
22.6
Yield on cost (5-Year) 4.37
PFE's Yield on cost (5-Year) is ranked higher than
91% of the 429 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. PFE: 4.37 )
PFE' s 10-Year Yield on cost (5-Year) Range
Min: 2.04   Max: 13.79
Current: 4.37

2.04
13.79
Share Buyback Rate 5.10
PFE's Share Buyback Rate is ranked higher than
94% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.70 vs. PFE: 5.10 )
PFE' s 10-Year Share Buyback Rate Range
Min: 5.1   Max: -19
Current: 5.1

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.90
PFE's Price/DCF (Projected) is ranked higher than
91% of the 349 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. PFE: 0.90 )
PFE' s 10-Year Price/DCF (Projected) Range
Min: 0.69   Max: 6.59
Current: 0.9

0.69
6.59
Price/Median PS Value 1.10
PFE's Price/Median PS Value is ranked higher than
71% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. PFE: 1.10 )
PFE' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 2.47
Current: 1.1

0.62
2.47
Price/Peter Lynch Fair Value 2.10
PFE's Price/Peter Lynch Fair Value is ranked higher than
55% of the 149 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. PFE: 2.10 )
PFE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.58   Max: 7.25
Current: 2.1

1.58
7.25
Earnings Yield (Greenblatt) 7.40
PFE's Earnings Yield (Greenblatt) is ranked higher than
81% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. PFE: 7.40 )
PFE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 12.6
Current: 7.4

1.4
12.6
Forward Rate of Return (Yacktman) 14.25
PFE's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. PFE: 14.25 )
PFE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.9   Max: 20.7
Current: 14.25

-3.9
20.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, RHHBY, NVS, ABT » details
Traded in other countries:PFZ.UK, PFEBC.Belgium, PFE.Sweden, PFE.Switzerland, PFE.Germany
Pfizer was founded in 1849 and is a global pharmaceutical firm which develops and produces medicines and vaccines for a range of conditions which include ares of immunology, inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. Pfizer's businesses include five prescription-only biopharmaceutical businesses and Pfizer Consumer Healthcare. Primary care, Specialty Care and Oncology are responsible for life-cycle management of in-line products and new proof of concept therapies. Pfizer's Board of Directors is responsible for the oversight of management, including the overall strategic direction of the company and for the company's policies on governance, executive compensation, transparency and compliance.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide